T. Rowe Price Associates
ENVB icon

T. Rowe Price Associates’s Enveric Biosciences ENVB Stock Holding History

T. Rowe Price Associates’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12
Closed -$35K – 2974
2022
Q1 		$35K Sell
12
-3
-20% -$13.3K ﹤0.01% 2942
2021
Q4 		$129K Buy
15
+9
+150% +$126K ﹤0.01% 2836
2021
Q3 		$110K Buy
+6
New +$116K ﹤0.01% 2826

Other funds holding ENVB

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's ENVB Position: Q2 2022 in Review

T. Rowe Price Associates sold out of Enveric Biosciences (ENVB) in Q2 2022, closing a stake of 12 shares — an estimated $35K sold.

T. Rowe Price Associates first reported a position in ENVB in Q3 2021 and held it in 3 quarters. The position peaked at $129K in Q4 2021. 21 funds tracked by Wall St. Rank hold ENVB as of Q2 2022.

  • T. Rowe Price Associates reported no remaining Enveric Biosciences position as of Q2 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 12 Enveric Biosciences shares in Q2 2022, an estimated $35K.
  • T. Rowe Price Associates first reported a position in Enveric Biosciences in Q3 2021 and held it in 3 quarters.
  • T. Rowe Price Associates's Enveric Biosciences position peaked at $129K in Q4 2021.
  • 21 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2022.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.